DoW Tick-Borne Disease Therapeutic/Diagnostic Research Award

About this funding opportunity

Summary: The intent of the fiscal year 2026 (FY26) Tick-Borne Disease Research Program (TBDRP) Therapeutic/Diagnostic Research Award (TDRA) is to support product-driven therapeutic and diagnostic development research aimed at reducing the burden of Lyme disease and/or other tick-borne diseases and conditions, and improving patient care and/or quality of life. Treatment-focused applications should be therapeutic evaluation studies designed to advance new ideas aimed at drug or treatment discovery that are still in the early/preclinical stages of development. Diagnosis-focused applications should propose diagnostic approaches that will be readily integrated into clinical settings.

https://cdmrp.health.mil/pubs/press/2026/tbdrppreann

Topic areas: General and Cross-cutting R&D, Life Sciences and Health, Security and Defense.

Funding amount

This grant provides Varies in funding.

Deadline

Applications are due Oct 22, 2026. Confirm the exact closing time on the official program page before applying.

Who can apply

This opportunity is open to the following applicant types:

• Open to all applicant types

Eligibility

The program did not publish a separate eligibility statement. See the official opportunity page for the full eligibility criteria.

Agency

DoW Tick-Borne Disease Therapeutic/Diagnostic Research Award is administered by Defense Health Agency Contracting Activity - DHACA (AMRAA), listed via Grants.gov.